Print Page  Close Window
Investor Overview
Company Overview
PDI is a leading health care commercialization company providing superior insight-driven, integrated multi-channel message delivery to established and emerging health care companies. The company is dedicated to enhancing engagement with health care practitioners and optimizing commercial investments for its clients by providing strategic flexibility, full product commercialization services, innovative multi-channel promotional solutions, and sales and marketing expertise.... More >>
Recent News
DateTitle 
10/14/14PDI, Inc. Announces Appointment of Graham G. Miao, MBA, Ph.D. as Chief Financial Officer
Brings Over 20 Years of Combined Financial and Healthcare Experience PARSIPPANY, N.J., Oct. 14, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, announced the appointment of Graham G. Miao, MBA, Ph.D., as its new Executive Vice President (EVP) and Chief Financial Officer (CFO), responsible for overseeing the company's financial and operational management to help drive its healthcare commercialization services and molecular diagnostics businesses. ... 
Printer Friendly Version
08/13/14PDI Reports 2014 Second Quarter Financial Results
Management Will Host Conference Call Tomorrow August 14 at 8:30 am ET PARSIPPANY, N.J., Aug. 13, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), today reported financial and operational results for the second quarter ended June 30, 2014. Summary financial and operational accomplishments include: Revenue of $31.6 million for the second quarter of 2014 Adjusted EBITDA (a non-GAAP financial measure) of $(1.5) million for the second quarter of 2014 On August 13, 2014, PDI acquired Asurage... 
Printer Friendly Version
08/13/14Molecular Diagnostics Veteran Heiner Dreismann, Ph.D., Joins PDI, Inc. Board of Directors
PARSIPPANY, N.J., Aug. 13, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, today announced that Heiner Dreismann, Ph.D., former president and chief executive officer of Roche Molecular Systems, Inc., has joined its board of directors. Effective immediately, his addition brings the total number of board members to seven. Dr. Dreismann possesses more than 27 years of global diagnostics experience in various positions at Roche Diagnostics and late... 
Printer Friendly Version
08/13/14PDI, Inc. Subsidiary Interpace Diagnostics Enters Molecular Diagnostics Market with Thyroid and Pancreatic Cancer Test Portfolio Acquisition
Transaction Marks First Step Toward Creation of a Molecular Diagnostics Subsidiary to Aid in Patient Diagnosis and Management PARSIPPANY, N.J., Aug. 13, 2014 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII), a leading healthcare commercialization company, today announced that its Interpace Diagnostics subsidiary has entered the expanding cancer molecular diagnostics market with the acquisition of the miRInform® Thyroid and Pancreas cancer test assets from privately held Asuragen, Inc. This acquisitio... 
Printer Friendly Version
More >>

Primary IR Contact
Asher Dewhurst
Westwick Partners
Phone: 443.213.0503
Email: Asher.Dewhurst@westwicke.com

Stock Quote
PDII (Common Stock)
ExchangeNASDAQ GM (US Dollar)
Price$1.71
Change (%) Stock is Down 0.08 (4.47%)
Volume29,427
Data as of 10/21/14 3:59 p.m. ET
Minimum 20 minute delay
Refresh quote
Webcasts
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.